None listed
Conditions
Interventions
Drug : K-MASTER liquid biopsy panel assays that a single active EGFR mutation (L858R or Exon19Del or G719X or L861Q) is accepted for the study Every twenty-eight days. A clinical study that receives o
Sponsors
The Catholic University of Korea, Seoul St. Mary's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Over 19 years old 2) Patients with arsenic cell lung cancer during the IIIB or IV phase, which have been confirmed systematically or genetically. 3) Clinical factors that are not available in the EGFR doryeonbyeoni mutant test or do not result in an EGFR doryeonbyeoni mutant (ex, women, non-smokers, etc.) 4) Patients who have identified a single active EGFR mutant during the K-MASTER liquid biopsies panel tests. 5) Patients with an expected dawn of time of at least three months with the eastern oncology cooperative group (ECOG) performed. 6) A measurable (measurable) or non-measurable (non-measurable) lesion is identified according to the tumor response assessment criteria (RECIST version 1.1). 7) Patients who have never taken the EGFR TKI treatment.
Exclusion criteria
Exclusion criteria: 1) The overindulgence of other malignant tumors. However, it is a highly treated non-Silicon skin cancer. Except for advanced solid cancers, where there is no evidence of disease for more than five years after the end of the treatment, and where the risk of relapse is virtually absent from the doctor's judgment 2) Evidence of serious or unadjusted systemic diseases that could endanger patients ' clinical trial participation or comply with clinical trial plans by the tester; Or, if there is evidence of active infection, including hepatitis B, hepatitis C and HIV. No screening of chronic conditions is required. 3) Unresolvable misrepresentation and vomiting, chronic gastrointestinal disease, and no swallowing of medicines that may prevent sufficient absorption of the test medication 4) Spinal compression 5) A brain transference that requires steroid therapy at least two weeks before the medication is administered. 6) Internal bleeding in the cephalopod confirmed unrelated to tumor 7) There is evidence of past history of epileptic lung disease (ILD), radiation pneumonia requiring steroid therapy, or a clinically active ILD. 8) If applicable to the following cardiovascular diseases - A history of congestive heart failure (CHF) with symptoms or serious heart arrhythmia that requires therapy. - A history of heart attack or unstable angina in six months before the first administration of the drug. - LVEF < 50%
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate, ORR | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival, PFS | — |
Countries
Korea, Republic of
Contacts
Public ContactJinHyoung Kang
The Catholic University of Korea, Seoul St. Mary's Hospital
Outcome results
None listed